Rupal Mehta1,2,3, Alexander Hodakowski2, Xuan Cai2, Kris E Lee4, Bryan R Kestenbaum5, Ian H de Boer5, Amani Fawzi6, Tien Yin Wong7, Joachim Ix8, Barbara Klein4, Ronald Klein4, Tamara Isakova1,2. 1. a Division of Nephrology , Northwestern University Feinberg School of Medicine , Chicago , IL , USA. 2. b Center for Translational Metabolism and Health, Institute of Public Health and Medicine, Northwestern University Feinberg School of Medicine , Chicago , IL , USA. 3. c Jesse Brown Veterans Administration Medical Center , Division of Nephrology , Chicago , IL , USA. 4. d Ocular Epidemiology Research Group, University of Wisconsin-Madison , Madison , WI , USA. 5. e Division of Nephrology , University of Washington , Seattle , WA , USA. 6. f Department of Ophthalmology , Northwestern University Feinberg School of Medicine , Chicago , IL , USA. 7. g Vitreo-Retinal Department , Singapore National Eye Centre , Singapore , Singapore. 8. h Division of Nephrology , University of California San Diego School of Medicine , San Diego , CA , USA.
Abstract
PURPOSE: Higher levels of serum phosphate are strongly linked to increased risk of cardiovascular disease and therapies aimed to lower serum phosphate are employed in the management of patients with chronic kidney disease (CKD). Data are limited, however, on serum phosphate as a risk factor for microvascular disease in community-based populations. It is important to determine the impact of novel risk factors, such as phosphate, on the microvasculature. METHODS: We conducted a prospective study of 3919 individuals in the Multi-Ethnic Study of Atherosclerosis (MESA) and 3544 individuals in the Beaver Dam Eye Study (BDES) to test the associations of serum phosphate with retinopathy and retinal vessel caliber, and change in retinopathy severity and change in retinal vessel caliber. RESULTS: Mean (standard deviation) serum phosphate was 3.66 (0.52) mg/dl in the MESA and 3.77 (0.55) mg/dl in the BDES. In multivariable adjusted models, phosphate was significantly associated with prevalent retinopathy in the MESA (Odds Ratio [OR] per 1 mg/dl increase in phosphate, 1.22; Confidence Interval [CI] 1.02-1.47) and the BDES (OR 1.06; CI 1.01-1.11). In stratified analyses, these relationships were even stronger and only seen in individuals with diabetes in both the MESA (OR 1.81; CI 1.30-2.53) and the BDES (OR 1.16; CI 1.05-1.29). Phosphate was not associated with incident or change in retinopathy severity, nor any retinal caliber outcome. CONCLUSIONS: Among community-living individuals with low prevalence of CKD, higher serum phosphate was associated with prevalent retinopathy in individuals with diabetes. Further longitudinal assessments in patients with diabetes necessitate further investigation.
PURPOSE: Higher levels of serum phosphate are strongly linked to increased risk of cardiovascular disease and therapies aimed to lower serum phosphate are employed in the management of patients with chronic kidney disease (CKD). Data are limited, however, on serum phosphate as a risk factor for microvascular disease in community-based populations. It is important to determine the impact of novel risk factors, such as phosphate, on the microvasculature. METHODS: We conducted a prospective study of 3919 individuals in the Multi-Ethnic Study of Atherosclerosis (MESA) and 3544 individuals in the Beaver Dam Eye Study (BDES) to test the associations of serum phosphate with retinopathy and retinal vessel caliber, and change in retinopathy severity and change in retinal vessel caliber. RESULTS: Mean (standard deviation) serum phosphate was 3.66 (0.52) mg/dl in the MESA and 3.77 (0.55) mg/dl in the BDES. In multivariable adjusted models, phosphate was significantly associated with prevalent retinopathy in the MESA (Odds Ratio [OR] per 1 mg/dl increase in phosphate, 1.22; Confidence Interval [CI] 1.02-1.47) and the BDES (OR 1.06; CI 1.01-1.11). In stratified analyses, these relationships were even stronger and only seen in individuals with diabetes in both the MESA (OR 1.81; CI 1.30-2.53) and the BDES (OR 1.16; CI 1.05-1.29). Phosphate was not associated with incident or change in retinopathy severity, nor any retinal caliber outcome. CONCLUSIONS: Among community-living individuals with low prevalence of CKD, higher serum phosphate was associated with prevalent retinopathy in individuals with diabetes. Further longitudinal assessments in patients with diabetes necessitate further investigation.
Authors: Tien Yin Wong; Michael D Knudtson; Ronald Klein; Barbara E K Klein; Stacy M Meuer; Larry D Hubbard Journal: Ophthalmology Date: 2004-06 Impact factor: 12.079
Authors: Jason P Linefsky; Kevin D O'Brien; Ronit Katz; Ian H de Boer; Eddy Barasch; Nancy S Jenny; David S Siscovick; Bryan Kestenbaum Journal: J Am Coll Cardiol Date: 2011-07-12 Impact factor: 24.094
Authors: Joachim H Ix; Michel Chonchol; Gail A Laughlin; Michael G Shlipak; Mary A Whooley Journal: Am J Kidney Dis Date: 2011-08-19 Impact factor: 8.860
Authors: Tien Yin Wong; Aruna Kamineni; Ronald Klein; A Richey Sharrett; Barbara E Klein; David S Siscovick; Mary Cushman; Bruce B Duncan Journal: Arch Intern Med Date: 2006-11-27
Authors: Sara B Seidelmann; Brian Claggett; Paco E Bravo; Ankur Gupta; Hoshang Farhad; Barbara E Klein; Ronald Klein; Marcelo Di Carli; Scott D Solomon Journal: Circulation Date: 2016-09-28 Impact factor: 29.690
Authors: Alun D Hughes; Emanuela Falaschetti; Nicholas Witt; Sumangali Wijetunge; Simon A McG Thom; Therese Tillin; Steve J Aldington; Nish Chaturvedi Journal: Stroke Date: 2016-10-11 Impact factor: 7.914
Authors: Charles Ginsberg; Alfons J H M Houben; Rakesh Malhotra; Tos T J M Berendschot; Pieter C Dagnelie; Jeroen P Kooman; Caroll A Webers; Coen D A Stehouwer; Joachim H Ix Journal: Clin J Am Soc Nephrol Date: 2019-09-20 Impact factor: 8.237
Authors: April C E van Gennip; Sanaz Sedaghat; Mercedes R Carnethon; Norrina B Allen; Barbara E K Klein; Mary Frances Cotch; Diana A Chirinos; Coen D A Stehouwer; Thomas T van Sloten Journal: Am J Epidemiol Date: 2022-03-24 Impact factor: 5.363